Pharmacokinetic_NP and_CC Pharmacodynamic_NP Profiles_NP of_IN Danofloxacin_NP Administered_NP by_IN Two_NP Dosing_NP Regimens_NP in_IN Calves_NP Infected_NP with_IN Mannheimia_NP (_( Pasteurella_NP )_) haemolytica_NN The_DT pharmacokinetics_NNS and_CC pharmacodynamics_NNS of_IN danofloxacin_NN in_IN calves_NNS with_IN induced_VBN Mannheimia_NP (_( Pasteurella_NP )_) haemolytica_NN pneumonia_NN were_VBD evaluated_VBN ._SENT Calves_NNS received_VBD either_DT saline_NN as_IN an_DT intravenous_JJ (_( IV_NP )_) bolus_NN or_CC danofloxacin_NN (_( 0.738_CD mg/kg_NN of_IN body_NN weight_NN )_) administered_VBN as_IN either_CC a_DT single_JJ IV_NP bolus_NN or_CC a_DT 36-h_JJ continuous_JJ IV_NP infusion_NN ._SENT Blood_NN samples_NNS and_CC bronchial_JJ secretions_NNS were_VBD collected_VBN before_IN and_CC at_IN predetermined_VBN times_NNS over_IN 48_CD h_NN following_VBG the_DT start_NN of_IN treatment_NN ._SENT Calves_NNS were_VBD assessed_VBN clinically_RB throughout_IN ,_, and_CC lung_NN consolidation_NN was_VBD assessed_VBN at_IN necropsy_NN ._SENT Bronchial_JJ secretions_NNS and_CC lung_NN tissue_NN were_VBD cultured_VBN for_IN M._NP haemolytica_NP ._SENT Bolus_NN administration_NN of_IN danofloxacin_NN produced_VBD a_DT high_JJ maximum_NN drug_NN concentration-to-MIC_JJ ratio_NN (_( Cmax:MIC_NP )_) of_IN 14.5_CD and_CC a_DT time_NN period_NN of_IN 9.1_CD h_NN when_WRB plasma_NN danofloxacin_NN concentrations_NNS exceeded_VBD the_DT MIC_NP (_( T>MIC_NP )_) ._SENT Following_VBG danofloxacin_NN infusion_NN ,_, the_DT Cmax:MIC_NP was_VBD low_JJ (_( 2.3_CD )_) ,_, with_IN a_DT long_RB T>MIC_JJ (_( 33.3_CD h_NN )_) ._SENT The_DT area_NN under_IN the_DT curve-to-MIC_JJ ratios_NNS were_VBD 43.3_CD and_CC 49.1_CD for_IN the_DT bolus_NN and_CC infusion_NN administrations_NNS ,_, respectively_RB ._SENT The_DT single_JJ bolus_NN of_IN danofloxacin_NN was_VBD more_RBR effective_JJ than_IN the_DT same_JJ dose_NN administered_VBN by_IN continuous_JJ infusion_NN ,_, as_RB indicated_VBN by_IN a_DT significantly_RB lower_JJR (_( P_NN <_SYM 0.05_CD )_) number_NN of_IN animals_NNS with_IN M._NP haemolytica_NN in_IN bronchial_JJ secretions_NNS after_IN treatment_NN and_CC lower_JJR rectal_JJ temperatures_NNS in_IN the_DT 24_CD h_NN after_IN the_DT start_NN of_IN treatment_NN ._SENT Thus_RB ,_, danofloxacin_NNS exhibited_VBD concentration-dependent_JJ antimicrobial_JJ activity_NN in_IN cattle_NNS with_IN respiratory_JJ disease_NN caused_VBN by_IN M._NP haemolytica_NP ._SENT Danofloxacin_NP is_VBZ a_DT fluoroquinolone_JJ antimicrobial_JJ drug_NN with_IN rapid_JJ bactericidal_JJ activity_NN against_IN a_DT broad_JJ range_NN of_IN pathogens_NNS responsible_JJ for_IN a_DT number_NN of_IN disease_NN syndromes_NNS of_IN economic_JJ importance_NN in_IN the_DT commercial_JJ rearing_NN of_IN livestock_NN ._SENT Since_IN their_PP$ introduction_NN in_IN the_DT late_JJ 1980s_NNS ,_, fluoroquinolones_NNS have_VBP been_VBN shown_VBN by_IN a_DT number_NN of_IN studies_NNS to_TO exhibit_VB concentration-dependent_JJ bactericidal_JJ activity_NN ,_, whereby_WRB the_DT optimal_JJ effect_NN is_VBZ attained_VBN by_IN the_DT administration_NN of_IN high_JJ doses_NNS over_IN a_DT short_JJ period_NN ._SENT This_DT is_VBZ a_DT property_NN shared_VBN by_IN the_DT aminoglycosides_NNS but_CC is_VBZ in_IN contrast_NN to_TO the_DT predominantly_RB time-dependent_JJ bactericidal_JJ action_NN shown_VBN by_IN the_DT beta-lactam_NN antibiotics_NNS ,_, where_WRB the_DT time_NN that_IN bacteria_NNS are_VBP exposed_VBN to_TO antimicrobial_JJ concentrations_NNS exceeding_VBG the_DT MIC_NP (_( T>MIC_NP )_) is_VBZ the_DT major_JJ determinant_NN of_IN efficacy_NN ._SENT These_DT different_JJ types_NNS of_IN action_NN have_VBP been_VBN confirmed_VBN for_IN danofloxacin_NN and_CC amoxicillin_NN in_IN an_DT in_IN vitro_NP pharmacodynamic_JJ model_NN against_IN Actinobacillus_NP pleuropneumoniae_NNS ._SENT The_DT purpose_NN of_IN this_DT study_NN was_VBD to_TO establish_VB the_DT pharmacokinetic_JJ and_CC pharmacodynamic_JJ properties_NNS of_IN danofloxacin_NN in_IN vivo_JJ by_IN using_VBG an_DT experimental_JJ model_NN of_IN calf_NN pneumonia_NN and_CC to_TO determine_VB whether_IN the_DT concentration-dependent_JJ activity_NN of_IN danofloxacin_NN in_IN cattle_NNS operates_VBZ under_IN simulated_JJ clinical_JJ conditions_NNS ._SENT A_DT fixed_VBN equal_JJ total_JJ dose_NN of_IN danofloxacin_NN was_VBD administered_VBN either_RB as_IN a_DT single_JJ intravenous_JJ (_( IV_NP )_) bolus_NN or_CC by_IN continuous_JJ infusion_NN over_IN a_DT 36-h_JJ period_NN ,_, and_CC the_DT clinical_JJ and_CC bacteriological_JJ outcomes_NNS in_IN calves_NNS with_IN induced_VBN infections_NNS of_IN Mannheimia_NP (_( Pasteurella_NP )_) haemolytica_NN were_VBD compared_VBN ._SENT The_DT study_NN was_VBD conducted_VBN in_IN compliance_NN with_IN Good_JJ Clinical_JJ Practice_NN guidelines_NNS ,_, the_DT analysis_NN of_IN samples_NNS was_VBD conducted_VBN in_IN accordance_NN with_IN Good_NP Laboratory_NP Practice_NP guidelines_NNS ,_, and_CC the_DT husbandry_NN of_IN all_DT animals_NNS was_VBD in_IN compliance_NN with_IN the_DT requirements_NNS of_IN national_JJ legislation_NN and_CC local_JJ animal_JJ welfare_NN guidelines_NNS ._SENT The_DT study_NN was_VBD conducted_VBN under_IN veterinary_JJ supervision_NN ,_, with_IN veterinary_JJ attention_NN available_JJ at_IN all_DT times_NNS ._SENT Animals_NNS ._SENT |_SYM Thirty-three_NP male_JJ Friesian_JJ calves_NNS (_( approximately_RB 11_CD to_TO 13_CD weeks_NNS of_IN age_NN ,_, with_IN initial_JJ body_NN weights_NNS of_IN 66.5_CD to_TO 106_CD kg_NN )_) were_VBD enrolled_VBN in_IN the_DT study_NN and_CC inoculated_VBN with_IN M._NP haemolytica_NP ._SENT Prior_RB to_TO enrollment_NN ,_, the_DT calves_NNS were_VBD free_JJ from_IN preexisting_VBG medical_JJ or_CC surgical_JJ conditions_NNS and_CC had_VBD no_DT history_NN of_IN previous_JJ respiratory_JJ disease_NN ._SENT Following_VBG enrollment_NN and_CC prior_RB to_TO inoculation_NN ,_, the_DT calves_NNS were_VBD allocated_VBN randomly_RB to_TO pens_NNS and_CC to_TO treatment_NN groups_NNS by_IN using_VBG an_DT incomplete_JJ block_NN design_NN ._SENT The_DT calves_NNS were_VBD housed_VBN in_IN straw-bedded_JJ pens_NNS in_IN a_DT self-contained_JJ naturally_RB ventilated_VBN calf_NN rearing_VBG unit_NN with_IN a_DT common_JJ airspace_NN ,_, but_CC divided_VBN by_IN solid_JJ partitions_NNS approximately_RB 1.4-m_NN high_JJ to_TO prevent_VB nasal_JJ contact_NN between_IN animals_NNS ,_, and_CC with_IN 4.4_CD m2_NN of_IN floor_NN space_NN per_IN calf_NN ._SENT Water_NN was_VBD supplied_VBN ad_NN libitum_NN ,_, and_CC the_DT calves_NNS were_VBD maintained_VBN on_IN an_DT antibiotic-free_JJ concentrate_NN diet_NN following_NN weaning_VBG at_IN 6_CD to_TO 7_CD weeks_NNS of_IN age_NN ._SENT On_IN arrival_NN at_IN the_DT study_NN site_NN ,_, at_IN approximately_RB 1_CD week_NN of_IN age_NN ,_, each_DT calf_NN received_VBD an_DT intramuscular_JJ injection_NN (_( 20_CD mg/kg_NN of_IN body_NN weight_NN )_) of_IN long-acting_VBG oxytetracycline_NN (_( Terramycin_NP LA_NP ;_: Pfizer_NP Ltd._NP ,_, Sandwich_NP ,_, United_NP Kingdom_NP )_) ._SENT There_EX was_VBD no_DT further_RBR antibiotic_JJ administration_NN prior_RB to_TO enrollment_NN and_CC treatment_NN with_IN the_DT test_NN materials_NNS ._SENT Inoculum_NN ._SENT |_SYM The_DT inoculum_NN was_VBD prepared_VBN by_IN transferring_VBG a_DT 1.0-ml_JJ aliquot_NN of_IN M._NP haemolytica_NP type_NN A1_JJ (_( reference_NN M7/2_NN )_) into_IN 9.0_CD ml_NN of_IN Oxoid_JJ nutrient_JJ broth_NN no_RB ._SENT 2_LS ._SENT After_IN incubation_NN at_IN 37C_JJ for_IN 16_CD to_TO 18_CD h_NN ,_, the_DT starter_JJ culture_NN was_VBD inoculated_VBN into_IN 290_CD ml_NN of_IN nutrient_JJ broth_NN ,_, shaken_VBN at_IN 150_CD rpm_NN ,_, and_CC incubated_VBD for_IN 4_CD h_NN to_TO provide_VB 300_CD ml_NN of_IN culture_NN ._SENT Following_VBG incubation_NN ,_, the_DT approximate_JJ viable_JJ count_NN (_( CFU_NP per_IN milliliter_NN )_) was_VBD determined_VBN by_IN using_VBG a_DT McFarland_NP scale_NN ._SENT Just_RB prior_RB to_TO inoculation_NN ,_, the_DT broth_NN culture_NN was_VBD diluted_VBN in_IN 1-liter_JJ volumes_NNS of_IN sterile_JJ phosphate-buffered_JJ saline_NN (_( 0.01_CD M_NP ,_, pH_NN =_SYM 7.4_CD ,_, prewarmed_VBN to_TO 37C_JJ )_) to_TO give_VB an_DT inoculum_NN with_IN an_DT approximate_JJ viable_JJ count_NN of_IN 3.3_CD x_SYM 105_CD CFU/ml_NP ._SENT The_DT titer_NN of_IN the_DT inoculum_NN was_VBD confirmed_VBN pre-_NN and_CC postinoculation_NN by_IN culture_NN on_IN blood_NN agar_NN ,_, following_VBG serial_JJ 10-fold_NN dilutions_NNS ,_, and_CC the_DT CFU_NP per_IN milliliter_NN were_VBD calculated_VBN by_IN multiplying_VBG the_DT number_NN of_IN colonies_NNS by_IN the_DT relevant_JJ dilution_NN factor_NN ._SENT Design_NN ._SENT |_SYM Animals_NNS selected_VBN for_IN the_DT study_NN were_VBD each_DT inoculated_VBN by_IN endobronchial_JJ deposition_NN (_( calves_NNS were_VBD conscious_JJ )_) over_IN a_DT period_NN of_IN approximately_RB 1_CD min_NN with_IN 300_CD ml_NN of_IN the_DT inoculum_NN ,_, representing_VBG an_DT inoculum_NN per_IN animal_NN of_IN approximately_RB 108_CD CFU_NP of_IN M._NP haemolytica_NP type_NN A1/calf_NP (_( acceptable_JJ range_NN was_VBD defined_VBN as_IN 5_CD x_NN 107_CD to_TO 5_CD x_SYM 108_CD CFU/calf_NN )_) ._SENT A_DT fiber-optic_JJ endoscope_NN sterilized_VBN with_IN ethylene_NN oxide_NN prior_RB to_TO the_DT start_NN of_IN inoculation_NN was_VBD inserted_VBN nasally_RB and_CC passed_VBN via_IN the_DT nasopharynx_NN into_IN the_DT trachea_NN ._SENT At_IN the_DT tracheal_JJ bifurcation_NN ,_, the_DT endoscope_NN was_VBD pushed_VBN approximately_RB 10_CD cm_NN into_IN the_DT principal_JJ bronchus_NN where_WRB the_DT inoculum_NN was_VBD deposited_VBN ._SENT Respiratory_JJ rates_NNS were_VBD assessed_VBN hourly_RB from_IN approximately_RB 3_CD h_NN after_IN the_DT inoculation_NN of_IN the_DT first_JJ calf_NN ._SENT When_WRB the_DT respiratory_JJ rates_NNS of_IN over_RB 72_CD %_NN of_IN the_DT inoculated_VBN calves_NNS had_VBD doubled_VBN from_IN those_DT recorded_VBN immediately_RB prior_RB to_TO inoculation_NN ,_, pretreatment_NN samples_NNS (_( blood_NN and_CC bronchial_JJ secretion_NN )_) were_VBD collected_VBN and_CC the_DT animals_NNS were_VBD administered_VBN their_PP$ allocated_VBN treatment_NN ._SENT Prior_RB to_TO administration_NN ,_, the_DT commercial_JJ danofloxacin_NN 18_CD %_NN formulation_NN (_( Advocin_NP 180_CD ;_: Pfizer_NP Ltd._NP )_) was_VBD diluted_VBN with_IN 0.9_CD %_NN (_( wt/vol_NN )_) sodium_NN chloride_NN to_TO give_VB solutions_NNS containing_VBG 6.0_CD and_CC 0.75_CD mg_NN of_IN danofloxacin/ml_NN for_IN use_NN as_IN test_NN materials_NNS ._SENT Sodium_NN chloride_NN (_( 0.9_CD %_NN [_SYM wt/vol_NN ]_SYM )_) was_VBD also_RB administered_VBN as_IN a_DT negative_JJ control_NN ._SENT Calves_NNS were_VBD randomly_RB allocated_VBN to_TO one_CD of_IN three_CD treatments_NNS (_( 11_CD animals_NNS per_IN treatment_NN )_) :_: danofloxacin_NP (_( 6_CD mg/ml_NN )_) administered_VBN as_IN a_DT single_JJ IV_NP bolus_NN injection_NN at_IN 0.738_CD mg/kg_NN ;_: danofloxacin_NP (_( 0.75_CD mg/ml_NN )_) administered_VBN as_IN a_DT continuous_JJ IV_NP infusion_NN over_IN 36_CD h_NN to_TO give_VB a_DT total_JJ infused_VBN dose_NN of_IN 0.645_CD mg/kg_NN ,_, following_VBG an_DT initial_JJ small_JJ IV_NP bolus_NN of_IN danofloxacin_NN (_( 6_CD mg/ml_NN )_) at_IN 0.093_CD mg/kg_NN ,_, to_TO give_VB a_DT total_JJ dose_NN of_IN 0.738_CD mg_NN of_IN danofloxacin/kg_NN ;_: or_CC saline_JJ at_IN 0.123_CD ml/kg_NN as_IN a_DT single_JJ IV_NP bolus_NN injection_NN to_TO give_VB a_DT dose_NN volume_NN equivalent_NN to_TO that_DT of_IN the_DT danofloxacin_NN bolus_NN treatment_NN ._SENT The_DT dose_NN regimen_NN for_IN the_DT danofloxacin_NN infusion_NN was_VBD calculated_VBN by_IN pharmacokinetic_JJ modeling_NN of_IN previously_RB obtained_VBN plasma_NN concentration-time_NN data_NNS as_IN the_DT dose_NN which_WDT would_MD provide_VB a_DT steady-state_NN concentration_NN in_IN plasma_NN slightly_RB exceeding_VBG the_DT MIC_NN for_IN the_DT M._NP haemolytica_NN strain_NN used_VBN in_IN the_DT respiratory_JJ infection_NN model_NN (_( MIC_NP =_SYM 30_CD ng/ml_NNS )_) when_WRB infused_VBN continuously_RB over_IN a_DT 36-h_JJ period_NN ._SENT Time_NN zero_NN was_VBD defined_VBN individually_RB for_IN each_DT calf_NN as_IN the_DT time_NN when_WRB treatment_NN administration_NN commenced_VBD ._SENT Injections_NNS were_VBD administered_VBN with_IN one_CD or_CC two_CD 10-ml_JJ disposable_JJ syringes_NNS via_IN an_DT IV_NP catheter_NN placed_VBD immediately_RB prior_JJ to_TO treatment_NN or_CC with_IN two_CD 1-ml_JJ disposable_JJ syringes_NNS via_IN the_DT indwelling_VBG catheter_NN in_IN animals_NNS to_TO be_VB infused_VBN ._SENT The_DT infusion_NN was_VBD delivered_VBN by_IN an_DT ambulatory_JJ infusion_NN pump_NN (_( CADD-PLUS_NP model_NN 5400_CD ;_: SIMS_NP Deltec_NP ,_, Inc._NP ,_, Minneapolis_NP ,_, Minn._NP )_) attached_VBD to_TO the_DT calf_NN 's_POS back_NN with_IN a_DT specially_RB designed_VBN pouch_NN and_CC harness_NN ._SENT An_DT 18-gauge_JJ indwelling_VBG catheter_NN (_( Leader-Flex_NP [_SYM PUR_NP ]_SYM Seldinger_NP catheter_NN ;_: Vygon_NP UK_NP Ltd._NP ,_, Cirencester_NP ,_, United_NP Kingdom_NP )_) was_VBD placed_VBN in_IN one_CD jugular_JJ vein_NN ,_, with_IN local_JJ anesthetic_NN being_VBG used_VBN ,_, and_CC secured_VBN by_IN cutaneous_JJ sutures_NNS ._SENT The_DT pump_NN was_VBD connected_VBN to_TO the_DT IV_NP catheter_NN in_IN the_DT jugular_JJ vein_NN via_IN an_DT opaque_JJ sterile_JJ giving_VBG set_NN (_( 1.5-m_JJ length_NN of_IN tubing_NN ,_, dead_JJ volume_NN of_IN 1.3_CD ml_NN ;_: Becton_NP Dickinson_NP ,_, Oxford_NP ,_, United_NP Kingdom_NP )_) ._SENT The_DT tubing_NN was_VBD secured_VBN to_TO the_DT animal_NN with_IN sutures_NNS and_CC tape_NN and_CC included_VBD several_JJ loops_NNS to_TO relieve_VB tension_NN ._SENT Prior_RB to_TO connection_NN of_IN the_DT pump_NN ,_, the_DT initial_JJ single_JJ bolus_NN was_VBD administered_VBN via_IN the_DT catheter_NN ,_, followed_VBN by_IN administration_NN of_IN 5_CD to_TO 10_CD ml_NN of_IN saline_NN ._SENT The_DT pump_NN was_VBD then_RB connected_VBN to_TO the_DT catheter_NN ,_, and_CC the_DT infusion_NN was_VBD initiated_VBN ._SENT The_DT pump_NN was_VBD set_VBN to_TO deliver_VB the_DT dose_NN volume_NN at_IN a_DT set_VBN rate_NN for_IN each_DT animal_NN such_JJ that_IN the_DT total_JJ dose_NN was_VBD delivered_VBN over_IN exactly_RB 36_CD h._NN The_DT body_NN weight_NN recorded_VBN for_IN each_DT animal_NN prior_RB to_TO inoculation_NN was_VBD used_VBN to_TO determine_VB the_DT dosages_NNS administered_VBN and_CC the_DT infusion_NN rate_NN ._SENT Clinical_JJ observations_NNS ._SENT |_SYM Clinical_JJ observations_NNS for_IN signs_NNS of_IN bovine_JJ respiratory_JJ disease_NN and_CC measurement_NN of_IN rectal_JJ temperature_NN were_VBD carried_VBN out_RP immediately_RB prior_RB to_TO inoculation_NN ,_, immediately_RB prior_RB to_TO treatment_NN administration_NN at_IN time_NN zero_CD ,_, and_CC at_IN 4_CD ,_, 8_CD ,_, 12_CD ,_, 24_CD ,_, 36_CD ,_, and_CC 48_CD h_NN thereafter_RB ._SENT The_DT respiratory_JJ rate_NN ,_, rectal_JJ temperature_NN ,_, character_NN of_IN respiration_NN ,_, and_CC general_JJ demeanor_NN were_VBD assessed_VBN for_IN each_DT calf_NN ._SENT The_DT veterinarian_NN making_VBG these_DT observations_NNS was_VBD unaware_JJ of_IN the_DT treatment_NN allocations_NNS of_IN the_DT animals_NNS receiving_VBG the_DT bolus_NN treatments_NNS (_( saline_NN and_CC danofloxacin_NN )_) ,_, although_IN the_DT presence_NN of_IN the_DT infusion_NN apparatus_NN made_VBD masking_VBG impossible_JJ for_IN calves_NNS receiving_VBG the_DT danofloxacin_NN infusion_NN ._SENT Any_DT calf_NN which_WDT was_VBD recumbent_JJ and_CC showed_VBD severe_JJ depression_NN and/or_CC signs_NNS of_IN respiratory_JJ distress_NN was_VBD immediately_RB euthanatized_JJ on_IN welfare_NN grounds_NNS ._SENT All_DT calves_NNS were_VBD euthanatized_JJ after_IN the_DT final_JJ sampling_NN (_( 48_CD h_NN after_IN the_DT start_NN of_IN treatment_NN )_) ._SENT At_IN necropsy_NN ,_, a_DT score_NN of_IN the_DT percentage_NN of_IN lung_NN consolidation_NN was_VBD estimated_VBN from_IN the_DT extent_NN of_IN visible_JJ consolidation_NN ,_, both_CC dorsally_RB and_CC ventrally_RB ,_, as_IN a_DT percentage_NN of_IN the_DT total_JJ lung_NN surface_NN area_NN ._SENT The_DT necropsies_NNS were_VBD performed_VBN by_IN an_DT experienced_JJ pathologist_NN who_WP was_VBD unaware_JJ of_IN the_DT treatment_NN allocation_NN ._SENT In_IN addition_NN ,_, lung_NN samples_NNS were_VBD collected_VBN at_IN necropsy_NN for_IN determination_NN of_IN viable_JJ counts_NNS of_IN M._NP haemolytica_NP ._SENT Sample_NN collection_NN and_CC handling_NN ._SENT |_SYM Blood_NP samples_NNS were_VBD collected_VBN immediately_RB prior_RB to_TO treatment_NN and_CC at_IN approximately_RB 15_CD ,_, 30_CD ,_, and_CC 45_CD min_NN and_CC 1_CD ,_, 1.5_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 6_CD ,_, 8_CD ,_, 10_CD ,_, 12_CD ,_, 18_CD ,_, 24_CD ,_, 36_CD ,_, and_CC 48_CD h_NN following_VBG single-bolus_NN administration_NN ._SENT For_IN animals_NNS receiving_VBG the_DT continuous_JJ infusion_NN ,_, blood_NN samples_NNS were_VBD collected_VBN immediately_RB before_IN treatment_NN and_CC then_RB approximately_RB 15_CD and_CC 30_CD min_NN and_CC 1_CD ,_, 2_CD ,_, 4_CD ,_, 8_CD ,_, 12_CD ,_, 16_CD ,_, 20_CD ,_, 24_CD ,_, 28_CD ,_, 32_CD ,_, 36_CD ,_, 36.5_CD ,_, 37_CD ,_, 38_CD ,_, 42_CD ,_, and_CC 48_CD h_NN after_IN the_DT start_NN of_IN administration_NN of_IN the_DT small_JJ loading_NN bolus_NN ._SENT Blood_NN samples_NNS (_( 5_CD ml_NN )_) were_VBD collected_VBN by_IN jugular_JJ venipuncture_NN of_IN the_DT vein_NN contralateral_JJ to_TO that_DT used_VBN for_IN treatment_NN administration_NN ,_, except_IN for_IN two_CD samples_NNS (_( at_IN 4_CD and_CC 10_CD h_NN )_) from_IN one_CD calf_NN receiving_VBG the_DT danofloxacin_NN single_JJ bolus_NN ,_, where_WRB the_DT ipsilateral_JJ vein_NN was_VBD used_VBN due_RB to_TO sampling_NN difficulties_NNS ._SENT Samples_NNS were_VBD collected_VBN using_VBG a_DT 1-inch_JJ by_IN 20-gauge_JJ sterile_JJ needle_NN and_CC were_VBD then_RB deposited_VBN into_IN blood_NN tubes_NNS with_IN heparin_NN anticoagulant_NN ._SENT The_DT blood_NN tubes_NNS were_VBD protected_VBN from_IN light_NN and_CC were_VBD centrifuged_VBN at_IN approximately_RB 1,400_CD x_NN g_NN for_IN 10_CD min_NN ,_, and_CC the_DT supernatant_JJ was_VBD transferred_VBN by_IN pipette_NN into_IN duplicate_JJ plastic_JJ tubes_NNS ._SENT Plasma_NN samples_NNS were_VBD stored_VBN at_IN approximately_RB -20C_NN prior_RB to_TO assay_VB ._SENT Measurement_NN of_IN concentrations_NNS of_IN danofloxacin_NN and_CC its_PP$ active_JJ metabolite_NN N-desmethyldanofloxacin_NN in_IN plasma_NN was_VBD performed_VBN by_IN using_VBG a_DT validated_VBN high-pressure_JJ liquid_JJ chromatography_NN method_NN with_IN solid-phase_NN extraction_NN and_CC fluorescence_NN detection_NN ._SENT The_DT limit_NN of_IN quantification_NN (_( LOQ_NP )_) was_VBD 10_CD ng/ml_NNS ._SENT Bronchial_JJ secretion_NN samples_NNS were_VBD collected_VBN from_IN each_DT animal_NN by_IN using_VBG an_DT established_JJ ,_, well-tolerated_JJ method_NN ._SENT Samples_NNS were_VBD collected_VBN following_VBG endotracheal_JJ intubation_NN approximately_RB 16_CD h_NN before_IN inoculation_NN ,_, immediately_RB before_IN treatment_NN administration_NN began_VBD ,_, and_CC at_IN approximately_RB 1_CD ,_, 3_CD ,_, 6_CD ,_, 12_CD ,_, 18_CD ,_, 24_CD ,_, 36_CD ,_, and_CC 48_CD h_NN thereafter_RB for_IN determination_NN of_IN viable_JJ counts_NNS of_IN M._NP haemolytica_NP ._SENT An_DT absorbent_JJ cotton_NN fabric_NN plug_NN ,_, fixed_VBN to_TO the_DT tip_NN of_IN a_DT solid_JJ flexible_JJ polyethylene_NN rod_NN ,_, was_VBD placed_VBN inside_IN a_DT sterile_JJ disposable_JJ stomach_NN tube_NN (_( one_CD per_IN animal_NN for_IN each_DT sample_NN )_) and_CC inserted_VBN into_IN the_DT trachea_NN orally_RB by_IN using_VBG a_DT laryngoscope_NN and_CC a_DT gag_NN ._SENT At_IN the_DT tracheal_JJ bifurcation_NN ,_, the_DT rod_NN was_VBD pushed_VBN approximately_RB 10_CD cm_NN beyond_IN the_DT end_NN of_IN the_DT stomach_NN tube_NN and_CC into_IN the_DT principal_JJ bronchus_NN ._SENT After_IN a_DT maximum_JJ residence_NN time_NN in_IN the_DT bronchus_NN of_IN 2_CD min_NN ,_, the_DT absorbent_JJ plug_NN was_VBD withdrawn_VBN into_IN the_DT stomach_NN tube_NN and_CC the_DT device_NN was_VBD removed_VBN from_IN the_DT animal_NN ._SENT The_DT absorptive_JJ cotton_NN plug_NN was_VBD placed_VBN in_IN a_DT disposable_JJ syringe_NN ,_, and_CC the_DT bronchial_JJ secretion_NN was_VBD extracted_VBN into_IN an_DT inert_JJ plastic_JJ sample_NN tube_NN by_IN manual_JJ pressure_NN ._SENT Sample_NN tubes_NNS were_VBD placed_VBN on_IN ice_NN and_CC kept_VBD in_IN the_DT dark_NN until_IN transferred_VBN to_TO the_DT laboratory_NN within_IN 1_CD h_NN for_IN immediate_JJ processing_NN to_TO determine_VB the_DT viable_JJ bacterial_JJ cell_NN counts_NNS ._SENT Following_VBG euthanasia_NN ,_, tissue_NN samples_NNS of_IN approximately_RB 0.5_CD g_NN each_DT were_VBD excised_VBN from_IN eight_CD standard_JJ sites_NNS in_IN the_DT lung_NN and_CC pooled_VBN to_TO give_VB four_CD samples_NNS per_IN calf_NN ._SENT Each_DT pooled_JJ sample_NN was_VBD weighed_VBN ,_, placed_VBN in_IN a_DT separate_JJ stomacher_NN bag_NN with_IN 9.0_CD ml_NN of_IN peptone_NN water_NN ,_, and_CC homogenized_VBN ._SENT M._NP haemolytica_NP counts_NNS were_VBD performed_VBN for_IN each_DT bronchial_JJ secretion_NN sample_NN and_CC each_DT lung_NN homogenate_NN following_VBG serial_JJ 10-fold_NN dilutions_NNS ._SENT Duplicate_JJ aliquots_NNS of_IN each_DT dilution_NN were_VBD cultured_VBN overnight_RB at_IN 37C_JJ on_IN blood_NN agar_NN ,_, and_CC the_DT mean_JJ colony_NN count_NN was_VBD used_VBN to_TO determine_VB the_DT mean_JJ viable_JJ count_NN of_IN each_DT sample_NN ._SENT The_DT four_CD pooled_JJ lung_NN samples_NNS per_IN calf_NN were_VBD counted_VBN separately_RB ,_, and_CC an_DT overall_JJ mean_NN was_VBD calculated_VBN for_IN each_DT calf_NN ._SENT Data_NP analysis_NN ._SENT |_SYM A_DT logarithmic_JJ transformation_NN (_( log_NN [_SYM bacteria_NNS count_NN +_SYM 1_CD ]_SYM )_) was_VBD applied_VBN to_TO the_DT M._NP haemolytica_NN counts_NNS (_( in_IN both_DT bronchial_JJ secretion_NN and_CC lung_NN tissue_NN samples_NNS )_) prior_RB to_TO analysis_NN ._SENT Bronchial_JJ secretion_NN bacterial_JJ counts_NNS ,_, respiration_NN rates_NNS ,_, and_CC rectal_JJ temperatures_NNS were_VBD analyzed_VBN by_IN using_VBG a_DT repeated_JJ measurement_NN model_NN with_IN the_DT pretreatment_NN value_NN as_IN a_DT covariate_NN ._SENT Lung_NN lesion_NN scores_NNS and_CC lung_NN tissue_NN bacterial_JJ counts_NNS were_VBD analyzed_VBN by_IN using_VBG a_DT general_JJ linear_JJ model_NN ._SENT A_DT categorical_JJ analysis_NN for_IN repeated_JJ measurements_NNS was_VBD carried_VBN out_RP separately_RB for_IN the_DT clinical_JJ scores_NNS for_IN respiration_NN and_CC demeanor_NN ._SENT The_DT proportion_NN of_IN animals_NNS completing_VBG the_DT study_NN in_IN each_DT treatment_NN group_NN (_( i.e._FW ,_, treatment_NN successes_NNS )_) was_VBD calculated_VBN as_IN the_DT number_NN of_IN calves_NNS completing_VBG the_DT study_NN at_IN 48_CD h_NN multiplied_VBN by_IN 100_CD and_CC divided_VBN by_IN the_DT difference_NN between_IN the_DT number_NN of_IN calves_NNS treated_VBN and_CC the_DT number_NN of_IN calves_NNS removed_VBN from_IN the_DT study_NN for_IN reasons_NNS not_RB related_VBN to_TO respiratory_JJ disease_NN ._SENT The_DT proportion_NN of_IN animals_NNS completing_VBG the_DT study_NN (_( treatment_NN successes_NNS )_) and_CC the_DT proportion_NN of_IN animals_NNS with_IN positive_JJ M._NP haemolytica_NN counts_VBZ in_IN posttreatment_NN bronchial_JJ secretions_NNS and_CC in_IN lung_NN tissue_NN samples_NNS were_VBD analyzed_VBN by_IN using_VBG a_DT logistic_JJ model_NN ._SENT A_DT priori_NN contrasts_NNS were_VBD used_VBN to_TO assess_VB differences_NNS between_IN treatments_NNS ._SENT The_DT 5_CD %_NN level_NN of_IN significance_NN (_( P_NN <=_0.05) MIC_NN was_VBD the_DT time_NN during_IN which_WDT plasma_NN danofloxacin_NN concentrations_NNS exceeded_VBD 30_CD ng/ml_NNS ._SENT Plasma_NN AUC0-infinity_NN was_VBD calculated_VBN as_IN AUC0-t_NP +_SYM Ct/lambdaz_NP ,_, where_WRB Ct_NP was_VBD the_DT last_JJ measurable_JJ plasma_NN danofloxacin_NN concentration_NN ._SENT The_DT ratio_NN of_IN AUC_NP to_TO MIC_NP (_( AUC:MIC_NP )_) was_VBD calculated_VBN as_IN AUC0-infinity/MIC_NP ._SENT The_DT plasma_NN Cmax(obs):MIC_NN was_VBD also_RB calculated_VBN ._SENT All_DT pharmacokinetic_JJ parameters_NNS and_CC concentrations_NNS of_IN danofloxacin_NN were_VBD calculated_VBN for_IN individual_JJ animals_NNS and_CC are_VBP presented_VBN as_IN means_NN +-_NN standard_JJ deviations_NNS (_( SD_NP )_) ,_, except_IN for_IN t1/2_JJ values_NNS ,_, which_WDT were_VBD calculated_VBN as_IN harmonic_JJ means_NNS ._SENT The_DT mean_JJ pharmacokinetic_JJ values_NNS for_IN danofloxacin_NN in_IN treated_VBN animals_NNS are_VBP presented_VBN in_IN Table_NP ._SENT Two_CD calves_NNS receiving_VBG continuous-infusion_NN treatment_NN were_VBD not_RB included_VBN in_IN the_DT calculation_NN of_IN mean_JJ pharmacokinetic_JJ parameters_NNS [_SYM except_IN for_IN Cp0_NP ,_, Cmax(obs)_NP ,_, and_CC Cmax(obs):MIC_NP ]_SYM ,_, since_IN they_PP were_VBD withdrawn_VBN from_IN the_DT study_NN on_IN welfare_NN grounds_NNS related_VBN to_TO severe_JJ respiratory_JJ disease_NN and_CC the_DT infusion_NN was_VBD terminated_VBN prior_RB to_TO the_DT 36-h_JJ assessment_NN time_NN ._SENT When_WRB danofloxacin_NN was_VBD administered_VBN as_IN a_DT single_JJ IV_NP bolus_NN ,_, peak_JJ plasma_NN drug_NN concentrations_NNS were_VBD obtained_VBN at_IN the_DT first_JJ sampling_NN time_NN point_NN ,_, 15_CD min_NN after_IN bolus_NN administration_NN ,_, with_IN a_DT mean_JJ Cmax(obs)_NN of_IN 436_CD ng/ml_NNS and_CC an_DT extrapolated_VBN Cp0_NN of_IN 589_CD ng/ml_NNS ._SENT Following_VBG rapid_JJ distribution_NN ,_, danofloxacin_NN was_VBD eliminated_VBN ,_, with_IN an_DT overall_JJ mean_JJ t1/2_NN of_IN 4.3_CD h._NN The_DT continuous_JJ IV_NP infusion_NN of_IN danofloxacin_NN was_VBD preceded_VBN by_IN the_DT administration_NN of_IN an_DT initial_JJ small_JJ IV_NP bolus_NN to_TO rapidly_RB achieve_VB the_DT target_NN steady-state_NN plasma_NN drug_NN concentration_NN of_IN >=30_JJ ng/ml_NNS ._SENT Peak_JJ plasma_NN danofloxacin_NN concentrations_NNS were_VBD detected_VBN at_IN the_DT first_JJ time_NN point_NN ,_, 15_CD min_NN after_IN administration_NN of_IN the_DT small_JJ bolus_NN ,_, with_IN a_DT mean_JJ Cmax(obs)_NN of_IN 69.0_CD ng/ml_NNS and_CC an_DT extrapolated_VBN Cp0_NN of_IN 85.8_CD ng/ml_NNS ._SENT Danofloxacin_NP concentrations_NNS declined_VBD rapidly_RB until_IN steady-state_NN concentrations_NNS slightly_RB higher_JJR than_IN 30_CD ng/ml_NNS were_VBD achieved_VBN approximately_RB 4_CD h_NN after_IN commencement_NN of_IN infusion_NN and_CC were_VBD maintained_VBN at_IN this_DT level_NN over_IN the_DT 36-h_JJ infusion_NN period_NN with_IN only_JJ minor_JJ fluctuations_NNS ._SENT Following_VBG the_DT end_NN of_IN the_DT IV_NP infusion_NN at_IN 36_CD h_NN ,_, the_DT pump_NN was_VBD disconnected_VBN and_CC plasma_NN danofloxacin_NN concentrations_NNS declined_VBD ,_, with_IN a_DT mean_JJ t1/2_NN of_IN 2.3_CD h._NNS The_DT administration_NN of_IN danofloxacin_NN as_IN a_DT single_JJ IV_NP bolus_NN produced_VBD a_DT high_JJ Cmax:MIC_NN of_IN 14.5_CD and_CC a_DT relatively_RB short_JJ T>MIC_NP of_IN 9.1_CD h_NN ._SENT In_IN contrast_NN ,_, when_WRB danofloxacin_NN was_VBD administered_VBN as_IN an_DT IV_NP infusion_NN over_IN 36_CD h_NN ,_, a_DT low_JJ Cmax:MIC_NN of_IN 2.3_CD was_VBD obtained_VBN and_CC steady-state_NN plasma_NN danofloxacin_NN concentrations_NNS were_VBD maintained_VBN above_IN the_DT MIC_NN for_IN a_DT prolonged_JJ period_NN ,_, resulting_VBG in_IN a_DT T>MIC_NP of_IN 33.3_CD h._NNS The_DT steady-state_NN concentrations_NNS achieved_VBN were_VBD as_RB intended_VBN ,_, i.e._FW ,_, slightly_RB in_IN excess_NN of_IN the_DT MIC_NP for_IN M._NP haemolytica_NP ,_, 30_CD ng/ml_NNS ._SENT The_DT plasma_NN AUC:MIC_JJ values_NNS for_IN the_DT single_JJ IV_NP bolus_NN and_CC the_DT continuous-infusion_NN danofloxacin_NN treatments_NNS were_VBD similar_JJ ,_, 43.3_CD and_CC 49.1_CD ,_, respectively_RB ._SENT N-Desmethyldanofloxacin_NP was_VBD not_RB detected_VBN at_IN measurable_JJ concentrations_NNS (_( LOQ_NP =_SYM 20_CD to_TO 50_CD ng/ml_NNS )_) at_IN any_DT time_NN point_NN in_IN any_DT animal_NN in_IN the_DT study_NN ,_, and_CC danofloxacin_NN was_VBD not_RB detected_VBN in_IN any_DT sample_NN from_IN a_DT control_NN animal_NN ._SENT The_DT number_NN of_IN animals_NNS withdrawn_VBN from_IN the_DT study_NN for_IN welfare_NN reasons_NNS due_JJ to_TO severe_JJ respiratory_JJ disease_NN was_VBD greater_JJR in_IN the_DT saline_JJ treatment_NN group_NN (_( 5_CD of_IN 11_CD ,_, 45.5_CD %_NN )_) than_IN in_IN either_CC the_DT danofloxacin_NN single-bolus_NN (_( 0_CD of_IN 11_CD ,_, 0_CD %_NN )_) or_CC the_DT danofloxacin_NN continuous-infusion_NN (_( 2_CD of_IN 11_CD ,_, 18.2_CD %_NN )_) treatment_NN group_NN ,_, although_IN the_DT difference_NN was_VBD only_RB statistically_RB significant_JJ (_( P_NN =_SYM 0.0037_CD )_) for_IN the_DT comparison_NN between_IN the_DT saline_NN and_CC the_DT danofloxacin_NN single-bolus_NN treatment_NN groups_NNS ._SENT There_EX were_VBD significant_JJ reductions_NNS in_IN the_DT number_NN of_IN animals_NNS with_IN M._NP haemolytica_NN in_IN bronchial_JJ secretions_NNS (_( P_NN <=_NN 0.0173_CD )_) and_CC in_IN lung_NN tissue_NN samples_NNS (_( P_NN <=_NN 0.0266_CD )_) for_IN each_DT of_IN the_DT danofloxacin_NN treatment_NN groups_NNS compared_VBN with_IN the_DT saline_JJ treatment_NN group_NN ._SENT In_IN addition_NN ,_, the_DT number_NN of_IN animals_NNS with_IN M._NP haemolytica_NN in_IN bronchial_JJ secretions_NNS was_VBD significantly_RB lower_JJR (_( P_NN =_SYM 0.0477_CD )_) for_IN the_DT danofloxacin_NN single-bolus_NN treatment_NN group_NN than_IN for_IN the_DT danofloxacin_NN continuous-infusion_NN treatment_NN group_NN ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS in_IN the_DT lung_NN lesion_NN scores_NNS between_IN the_DT treatment_NN groups_NNS ._SENT M._NP haemolytica_NP was_VBD isolated_VBN from_IN bronchial_JJ secretion_NN samples_NNS in_IN some_DT of_IN the_DT animals_NNS in_IN the_DT saline_JJ treatment_NN group_NN at_IN each_DT assessment_NN time_NN after_IN treatment_NN and_CC in_IN the_DT majority_NN of_IN postmortem_JJ lung_NN tissue_NN samples_NNS in_IN these_DT animals_NNS ._SENT In_IN comparison_NN ,_, M._NP haemolytica_NP was_VBD isolated_VBN only_RB at_IN a_DT very_RB low_JJ count_NN from_IN one_CD animal_NN at_IN 48_CD h_NN after_IN administration_NN of_IN a_DT single_JJ bolus_NN of_IN danofloxacin_NN ,_, and_CC low_JJ counts_NNS were_VBD recovered_VBN from_IN five_CD animals_NNS in_IN the_DT continuous-infusion_NN treatment_NN group_NN ._SENT Compared_VBN with_IN the_DT saline_JJ treatment_NN ,_, each_DT of_IN the_DT danofloxacin_NN treatments_NNS resulted_VBD in_IN significantly_RB lower_JJR M._NP haemolytica_NN counts_NNS in_IN bronchial_JJ secretions_NNS (_( P_NN <=_NN 0.0001_CD )_) collected_VBN from_IN 3_CD to_TO 48_CD h_NN ,_, inclusive_JJ ,_, and_CC in_IN lung_NN tissue_NN samples_NNS (_( P_NN <=_NN 0.0053_CD )_) ;_: however_RB ,_, the_DT differences_NNS between_IN the_DT results_NNS for_IN the_DT two_CD danofloxacin_NN treatment_NN regimens_NNS were_VBD not_RB significant_JJ ._SENT Animals_NNS treated_VBN with_IN each_DT of_IN the_DT danofloxacin_NN regimens_NNS showed_VBD greater_JJR clinical_JJ improvements_NNS (_( character_NN of_IN respiration_NN and_CC general_JJ demeanor_NN )_) than_IN those_DT in_IN the_DT saline_JJ control_NN group_NN (_( Tables_NP and_NP )_) ,_, and_CC animals_NNS treated_VBN with_IN single-bolus_NN administrations_NNS of_IN danofloxacin_NN tended_VBN to_TO have_VB greater_JJR clinical_JJ improvement_NN than_IN those_DT treated_VBN with_IN the_DT continuous_JJ infusion_NN ._SENT Compared_VBN with_IN animals_NNS in_IN the_DT saline_JJ treatment_NN group_NN ,_, the_DT animals_NNS in_IN both_DT danofloxacin_NN treatment_NN groups_NNS showed_VBD a_DT significant_JJ improvement_NN in_IN demeanor_NN from_IN 0_CD to_TO 48_CD h_NN (_( P_NN <=_NN 0.0097_CD )_) ;_: although_IN the_DT demeanor_NN of_IN the_DT animals_NNS in_IN the_DT continuous-infusion_NN treatment_NN group_NN was_VBD significantly_RB different_JJ from_IN that_DT of_IN the_DT animals_NNS in_IN the_DT saline_JJ control_NN group_NN from_IN 0_CD to_TO 24_CD h_NN (_( P_NN <=_NN 0.0151_CD )_) ,_, the_DT demeanor_NN of_IN the_DT animals_NNS in_IN the_DT single-bolus_NN treatment_NN group_NN was_VBD not_RB ._SENT However_RB ,_, for_IN improvement_NN in_IN the_DT character_NN of_IN respiration_NN ,_, the_DT single-bolus_NN treatment_NN produced_VBD significantly_RB better_JJR results_NNS than_IN the_DT saline_JJ treatment_NN at_IN 24_CD and_CC 48_CD h_NN (_( P_NN <=_NN 0.0416_CD )_) ._SENT The_DT difference_NN between_IN the_DT results_NNS with_IN continuous-infusion_NN treatment_NN and_CC saline_JJ treatment_NN was_VBD not_RB significant_JJ ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS in_IN rectal_JJ temperatures_NNS between_IN animals_NNS receiving_VBG the_DT saline_NN and_CC continuous-infusion_NN treatments_NNS ;_: however_RB ,_, for_IN those_DT receiving_VBG the_DT single-bolus_NN treatment_NN ,_, rectal_JJ temperatures_NNS were_VBD significantly_RB lower_JJR than_IN for_IN those_DT receiving_VBG saline_JJ treatment_NN (_( P_NN <=_NN 0.0167_CD )_) at_IN 12_CD and_CC 24_CD h_NN and_CC significantly_RB lower_JJR (_( P_NN <=_NN 0.0075_CD )_) than_IN for_IN those_DT receiving_VBG the_DT infusion_NN at_IN 8_CD ,_, 12_CD ,_, and_CC 24_CD h_NN after_IN the_DT commencement_NN of_IN treatment_NN ._SENT Respiratory_JJ rates_NNS were_VBD generally_RB lower_JJR in_IN animals_NNS in_IN either_DT danofloxacin_NN treatment_NN group_NN than_IN in_IN animals_NNS in_IN the_DT saline_JJ control_NN group_NN ,_, except_IN at_IN the_DT 36-_CD and_CC 48-h_JJ time_NN points_NNS ._SENT The_DT reduction_NN in_IN respiratory_JJ rate_NN was_VBD greatest_JJ at_IN 8_CD and_CC 12_CD h_NN for_IN animals_NNS receiving_VBG the_DT single_JJ bolus_NN ,_, but_CC this_DT result_NN was_VBD not_RB significantly_RB different_JJ from_IN that_DT seen_VBN with_IN animals_NNS receiving_VBG saline_JJ ._SENT At_IN 36_CD and_CC 48_CD h_NN ,_, the_DT respiratory_JJ rates_NNS for_IN animals_NNS receiving_VBG single-bolus_NN danofloxacin_NN treatment_NN were_VBD higher_JJR than_IN for_IN those_DT receiving_NN either_CC saline_NN or_CC continuous-infusion_NN treatments_NNS ;_: however_RB ,_, at_IN these_DT time_NN points_NNS ,_, no_DT animals_NNS had_VBD been_VBN withdrawn_VBN from_IN the_DT single-bolus_NN treatment_NN group_NN ,_, while_IN four_CD and_CC five_CD calves_NNS were_VBD withdrawn_VBN (_( at_IN 36_CD and_CC 48_CD h_NN ,_, respectively_RB )_) from_IN the_DT saline_JJ treatment_NN group_NN and_CC two_CD calves_NNS were_VBD withdrawn_VBN from_IN the_DT continuous-infusion_NN treatment_NN group_NN because_IN they_PP showed_VBD severe_JJ respiratory_JJ disease_NN ._SENT Thus_RB ,_, the_DT interpretation_NN of_IN data_NNS between_IN treatments_NNS at_IN these_DT time_NN points_NNS is_VBZ difficult_JJ as_IN only_RB those_DT calves_NNS remaining_VBG in_IN the_DT study_NN were_VBD included_VBN for_IN saline_NN and_CC danofloxacin_NN infusion_NN ,_, so_RB the_DT results_NNS from_IN the_DT early_JJ time_NN points_NNS (_( 0_CD to_TO 24_CD h_NN )_) give_VBP a_DT more_RBR accurate_JJ indication_NN of_IN the_DT clinical_JJ response_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Pharmacokinetics_NP and_CC pharmacodynamics_NNS of_IN danofloxacin_NN in_IN cattle_NNS with_IN respiratory_JJ disease_NN ._SENT Pharmacokinetics_NNS and_CC pharmacodynamics_NNS of_IN danofloxacin_NN in_IN cattle_NNS with_IN respiratory_JJ disease_NN ._SENT Shown_VBN are_VBP plasma_NN danofloxacin_NN concentrations_NNS (_( means_NN +-_NN SD_NNS )_) following_VBG administration_NN as_IN a_DT single_JJ IV_NP bolus_NN or_CC as_IN a_DT continuous_JJ IV_NP infusion_NN ._SENT TABLE_NN 1_CD |_SYM Mean_NP pharmacokinetic_JJ parameters_NNS for_IN danofloxacin_NN in_IN cattle_NNS with_IN respiratory_JJ disease_NN following_VBG administration_NN either_CC as_IN a_DT single_JJ bolus_NN or_CC as_IN a_DT continuous_JJ infusion_NN TABLE_NP 2_CD |_SYM Lung_NP lesion_NN scores_NNS and_CC classification_NN of_IN animals_NNS by_IN presence_NN of_IN M._NP haemolytica_NP in_IN posttreatment_NN bronchial_JJ secretions_NNS and_CC in_IN lung_NN tissue_NN samples_NNS TABLE_NP 3_CD |_SYM Geometric_JJ mean_JJ M._NP haemolytica_NN counts_NNS in_IN bronchial_JJ secretions_NNS and_CC lung_NN tissue_NN samples_NNS TABLE_NP 4_CD |_SYM Frequency_NN distribution_NN of_IN clinical_JJ signs_NNS (_( assessment_NN of_IN demeanor_NN )_) TABLE_NP 5_CD |_SYM Frequency_NN distribution_NN of_IN clinical_JJ signs_NNS (_( assessment_NN of_IN character_NN of_IN respiration_NN )_) The_DT pharmacokinetics_NN of_IN danofloxacin_NN has_VBZ been_VBN investigated_VBN in_IN ruminant_JJ species_NNS including_VBG cattle_NNS ,_, sheep_NN ,_, and_CC goats_NNS ._SENT Following_VBG administration_NN of_IN danofloxacin_NN ,_, there_EX is_VBZ rapid_JJ distribution_NN to_TO the_DT lungs_NNS and_CC high_JJ tissue_NN concentrations_NNS are_VBP achieved_VBN in_IN pneumonic_JJ lung_NN ,_, including_VBG areas_NNS of_IN consolidation_NN ._SENT Danofloxacin_NP has_VBZ a_DT broad_JJ range_NN of_IN activity_NN against_IN bacteria_NNS and_CC mycoplasmas_NNS involved_VBN in_IN bovine_JJ respiratory_JJ disease_NN and_CC is_VBZ known_VBN to_TO have_VB a_DT rapid_JJ bactericidal_JJ effect_NN in_IN vitro_NN against_IN M._NP haemolytica_NP ._SENT The_DT concentration-dependent_JJ killing_NN profile_NN is_VBZ associated_VBN with_IN a_DT relatively_RB prolonged_JJ postantibiotic_JJ effect_NN ._SENT The_DT purpose_NN of_IN this_DT study_NN was_VBD to_TO evaluate_VB the_DT pharmacokinetic_JJ and_CC pharmacodynamic_JJ characteristics_NNS of_IN danofloxacin_NN in_IN an_DT in_IN vivo_JJ model_NN of_IN M._NP haemolytica_NP pneumonia_NN in_IN calves_NNS ._SENT This_DT evaluation_NN was_VBD carried_VBN out_RP by_IN comparing_VBG the_DT clinical_JJ and_CC bacteriological_JJ outcomes_NNS of_IN two_CD regimens_NNS with_IN predetermined_VBN equal_JJ total_JJ doses_NNS of_IN danofloxacin_NN administered_VBN to_TO calves_NNS with_IN a_DT respiratory_JJ infection_NN ,_, thus_RB establishing_VBG whether_IN or_CC not_RB danofloxacin_NN exhibits_VBZ a_DT concentration-dependent_JJ bactericidal_JJ effect_NN in_IN cattle_NNS ._SENT The_DT same_JJ total_JJ dose_NN of_IN danofloxacin_NN (_( 0.738_CD mg/kg_NN )_) was_VBD administered_VBN either_RB as_IN a_DT single_JJ IV_NP bolus_NN injection_NN or_CC as_IN a_DT prolonged_JJ continuous_JJ IV_NP infusion_NN ._SENT The_DT single_JJ IV_NP bolus_NN of_IN danofloxacin_NN was_VBD predicted_VBN to_TO give_VB a_DT high_JJ Cmax:MIC_NP and_CC a_DT short_JJ T>MIC_NP ,_, while_IN the_DT IV_NP infusion_NN of_IN danofloxacin_NN was_VBD predicted_VBN to_TO give_VB a_DT low_JJ Cmax:MIC_NP and_CC a_DT long_JJ T>MIC_NP ._SENT As_IN predicted_VBN ,_, for_IN those_DT calves_NNS receiving_VBG the_DT danofloxacin_NN infusion_NN treatment_NN ,_, concentrations_NNS in_IN plasma_NN were_VBD maintained_VBN above_IN the_DT MIC_NN for_IN the_DT majority_NN of_IN the_DT 36-h_JJ period_NN (_( T>MIC_NP =_SYM 33.3_CD h_NN )_) ._SENT In_IN contrast_NN ,_, for_IN those_DT calves_NNS receiving_VBG the_DT single_JJ bolus_NN of_IN danofloxacin_NN ,_, concentrations_NNS in_IN plasma_NN exceeded_VBD the_DT MIC_NN for_IN less_JJR than_IN 10_CD h_NN posttreatment_NN ._SENT The_DT initial_JJ distribution_NN of_IN danofloxacin_NN following_VBG the_DT single_JJ IV_NP bolus_NN was_VBD rapid_JJ ,_, and_CC this_DT was_VBD followed_VBN by_IN an_DT elimination_NN phase_NN which_WDT was_VBD monitored_VBN for_IN 12_CD h_NN postadministration_NN ,_, after_IN which_WDT concentrations_NNS fell_VBD below_IN the_DT LOQ_NP ._SENT The_DT graph_NN shown_VBN in_IN Fig._NN suggests_VBZ a_DT multiexponential_JJ elimination_NN curve_NN with_IN a_DT terminal_JJ elimination_NN phase_NN slope_NN evident_JJ after_IN 2_CD to_TO 3_CD h_NN postadministration_NN ._SENT For_IN calves_NNS receiving_VBG danofloxacin_NN by_IN continuous_JJ infusion_NN ,_, the_DT initial_JJ distribution_NN following_VBG the_DT loading_NN bolus_NN was_VBD also_RB rapid_JJ and_CC steady-state_NN concentrations_NNS were_VBD achieved_VBN from_IN 2_CD to_TO 4_CD h_NN after_IN the_DT first_JJ administration_NN ,_, with_IN only_RB minor_JJ fluctuations_NNS until_IN the_DT cessation_NN of_IN the_DT infusion_NN ._SENT The_DT mean_JJ AUC0-infinity_NN estimates_NNS for_IN the_DT continuous-infusion_NN (_( 1,472_CD ng_NNS h/ml_NN )_) and_CC single-bolus_NN (_( 1,298_CD ng_NNS h/ml_NN )_) treatments_NNS represented_VBD only_RB small_JJ extrapolations_NNS over_IN the_DT mean_JJ AUC0-t_NP estimates_NNS (_( 1,412_CD ng_NNS h/ml_NN and_CC 1,190_CD ng_NNS h/ml_NN ,_, respectively_RB )_) ,_, and_CC the_DT similarities_NNS in_IN the_DT estimates_NNS of_IN AUC0-infinity_NN for_IN both_DT routes_NNS confirm_VBP that_IN the_DT total_JJ doses_NNS administered_VBN were_VBD equivalent_JJ overall_RB ._SENT Thus_RB ,_, the_DT AUC:MIC_JJ estimates_NNS for_IN each_DT treatment_NN regimen_NN were_VBD also_RB similar_JJ (_( 49.07_CD for_IN the_DT infusion_NN treatment_NN compared_VBN with_IN 43.27_CD for_IN the_DT bolus_NN treatment_NN )_) ,_, as_RB were_VBD the_DT values_NNS for_IN CLb_NP for_IN both_DT treatments_NNS (_( 507.8_CD and_CC 578.2_CD ml/h_NN kg_NN ,_, respectively_RB )_) ._SENT However_RB ,_, the_DT t1/2_NN and_CC lambdaz_NN values_NNS for_IN the_DT two_CD regimens_NNS were_VBD different_JJ (_( 2.3_CD h_NN and_CC 0.3052_CD h-1_NN ,_, respectively_RB ,_, for_IN the_DT infusion_NN treatment_NN compared_VBN with_IN 4.3_CD h_NN and_CC 0.1597_CD h-1_NN for_IN the_DT bolus_NN treatment_NN )_) ._SENT These_DT apparent_JJ differences_NNS in_IN the_DT t1/2_NN may_MD have_VB resulted_VBN from_IN differences_NNS in_IN the_DT number_NN of_IN time_NN points_NNS used_VBN to_TO estimate_VB the_DT terminal_JJ elimination_NN rate_NN constant_JJ in_IN the_DT bolus_NN treatment_NN group_NN compared_VBN with_IN that_DT in_IN the_DT danofloxacin_NN infusion_NN group_NN ._SENT In_IN this_DT study_NN ,_, danofloxacin_NN administered_VBN either_RB as_IN a_DT single_JJ bolus_NN or_CC as_IN a_DT continuous_JJ infusion_NN was_VBD significantly_RB more_RBR effective_JJ in_IN the_DT treatment_NN of_IN M._NP haemolytica_NP infection_NN in_IN calves_NNS than_IN the_DT control_NN saline_JJ treatment_NN ._SENT Overall_RB ,_, the_DT administration_NN of_IN danofloxacin_NN as_IN a_DT single_JJ bolus_NN was_VBD more_RBR effective_JJ than_IN administration_NN of_IN the_DT same_JJ dose_NN as_IN a_DT continuous_JJ infusion_NN ,_, as_RB reflected_VBN in_IN a_DT higher_JJR percentage_NN of_IN animals_NNS successfully_RB completing_VBG the_DT study_NN ,_, significantly_RB lower_JJR rectal_JJ temperatures_NNS over_IN the_DT initial_JJ 24-h_JJ period_NN ,_, and_CC a_DT significantly_RB lower_JJR number_NN of_IN animals_NNS with_IN M._NP haemolytica_NN in_IN bronchial_JJ secretions_NNS ._SENT This_DT was_VBD in_IN spite_NN of_IN the_DT marginally_RB lower_RBR AUC:MIC_JJ for_IN danofloxacin_NN following_VBG bolus_NN administration_NN ._SENT These_DT data_NNS establish_VB that_DT danofloxacin_NN exhibits_VBZ a_DT concentration-dependent_JJ antimicrobial_JJ activity_NN when_WRB administered_VBN to_TO the_DT target_NN species_NNS ,_, cattle_NNS ,_, with_IN respiratory_JJ disease_NN caused_VBN by_IN M._NP haemolytica_NN under_IN conditions_NNS that_WDT closely_RB simulated_VBD field_NN conditions_NNS ._SENT Therefore_RB ,_, these_DT data_NNS suggest_VBP that_IN maximum_JJ therapeutic_JJ benefits_NNS can_MD be_VB obtained_VBN with_IN danofloxacin_NN with_IN the_DT administration_NN of_IN high_JJ doses_NNS over_IN short_JJ periods_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, the_DT Cmax:MIC_NP for_IN the_DT bolus_NN regimen_NN was_VBD 14.5_CD ._SENT In_IN a_DT previous_JJ in_IN vitro_NP pharmacodynamic_JJ model_NN ,_, in_IN which_WDT danofloxacin_NN was_VBD shown_VBN to_TO have_VB concentration-dependent_JJ bactericidal_JJ action_NN against_IN Actinobacillus_NP pleuropneumoniae_NNS ,_, danofloxacin_NNS showed_VBD maximal_JJ bactericidal_JJ effect_NN and_CC there_EX was_VBD no_DT regrowth_NN observed_VBD when_WRB the_DT Cmax_NP was_VBD at_IN least_JJS eight_CD times_NNS the_DT MIC_NN ._SENT The_DT extent_NN of_IN protein_NN binding_VBG of_IN danofloxacin_NN in_IN plasma_NN was_VBD not_RB determined_VBN in_IN the_DT present_JJ study_NN ,_, and_CC the_DT concentrations_NNS and_CC pharmacokinetic_JJ values_NNS presented_VBD correspond_VB to_TO total_JJ danofloxacin_NN ._SENT However_RB ,_, the_DT extent_NN of_IN protein_NN binding_VBG of_IN danofloxacin_NN was_VBD determined_VBN in_IN previous_JJ studies_NNS and_CC can_MD be_VB described_VBN as_IN reversible_JJ and_CC relatively_RB low_JJ ,_, with_IN values_NNS of_IN approximately_RB 49_CD %_NN in_IN bovine_JJ plasma_NN and_CC 31_CD and_CC 14_CD %_NN in_IN bovine_JJ bronchial_JJ secretions_NNS and_CC nasal_JJ secretions_NNS ,_, respectively_RB ._SENT In_IN addition_NN ,_, danofloxacin_NN has_VBZ been_VBN shown_VBN to_TO achieve_VB concentrations_NNS in_IN lungs_NNS and_CC in_IN bronchial_JJ mucosa_NN that_WDT are_VBP approximately_RB fivefold_JJ and_CC threefold_RB higher_JJR ,_, respectively_RB ,_, than_IN that_WDT achieved_VBD in_IN plasma_NN ._SENT Therefore_RB ,_, the_DT steady-state_NN free-drug_NN concentrations_NNS achieved_VBN in_IN the_DT target_NN tissues_VBZ (_( i.e._FW ,_, bronchi_NNS and_CC lungs_NNS )_) during_IN the_DT present_JJ study_NN would_MD have_VB largely_RB exceeded_VBN the_DT MICs_NP for_IN M._NP haemolytica_NP ._SENT Thus_RB ,_, the_DT concentration-dependent_JJ activity_NN observed_VBD with_IN danofloxacin_NN can_MD be_VB considered_VBN as_IN a_DT real_JJ effect_NN rather_RB than_IN the_DT result_NN of_IN subtherapeutic_JJ concentrations_NNS in_IN animals_NNS treated_VBN with_IN danofloxacin_NN administered_VBN as_IN an_DT IV_NP infusion_NN ._SENT In_IN addition_NN to_TO the_DT correlation_NN of_IN increased_VBN efficacy_NN with_IN high_JJ Cmax-to-MIC_JJ and_CC AUC-to-MIC_JJ ratios_NNS ,_, high_JJ Cmax-to-MIC_JJ ratios_NNS have_VBP also_RB been_VBN shown_VBN to_TO minimize_VB the_DT potential_NN for_IN the_DT development_NN of_IN resistance_NN to_TO fluoroquinolones_NNS ._SENT This_DT characteristic_NN has_VBZ been_VBN established_VBN in_IN several_JJ studies_NNS where_WRB the_DT development_NN of_IN resistance_NN to_TO fluoroquinolones_NNS could_MD be_VB eliminated_VBN or_CC drastically_RB reduced_VBN when_WRB concentrations_NNS of_IN the_DT antimicrobial_JJ drug_NN to_TO which_WDT the_DT bacteria_NNS were_VBD exposed_VBN exceeded_VBD the_DT MIC_NN by_IN at_IN least_JJS 8-_CD to_TO 10-fold_NN ._SENT The_DT pharmacokinetic_JJ and_CC pharmacodynamic_JJ evaluation_NN of_IN danofloxacin_NN in_IN this_DT M._NP haemolytica_NN pneumonia_NN model_NN in_IN calves_NNS has_VBZ demonstrated_VBN the_DT concentration-dependent_JJ activity_NN of_IN this_DT drug_NN in_IN cattle_NNS ._SENT The_DT principle_NN of_IN a_DT concentration-dependent_JJ approach_NN to_TO therapy_NN has_VBZ been_VBN used_VBN to_TO select_VB the_DT commercial_JJ dose_NN of_IN danofloxacin_NN in_IN the_DT 18_CD %_NN formulation_NN as_IN 6_CD mg/kg_NN administered_VBN subcutaneously_RB either_CC once_RB or_CC ,_, if_IN clinically_RB required_VBN ,_, twice_RB 48_CD h_NN apart_RB ._SENT This_DT selection_NN is_VBZ based_VBN on_IN relating_VBG the_DT AUC:MIC_JJ and_CC Cmax:MIC_JJ results_NNS to_TO recently_RB determined_VBN MICs_NNS for_IN field_NN isolates_NNS of_IN susceptible_JJ pathogens_NNS such_JJ as_IN M._NP haemolytica_NP (_( with_IN MICs_NP ranging_VBG from_IN 0.015_CD to_TO 2_CD mug/ml_NN ,_, an_DT MIC_NN at_IN which_WDT 50_CD %_NN of_IN isolates_NNS are_VBP inhibited_VBN of_IN 0.06_CD mug/ml_NN ,_, and_CC an_DT MIC_NN at_IN which_WDT 90_CD %_NN of_IN isolates_NNS are_VBP inhibited_VBN of_IN 0.25_CD mug/ml_NN [_SYM data_NNS not_RB shown_VBN ]_SYM )_) ._SENT It_PP is_VBZ proposed_VBN that_IN this_DT concept_NN will_MD maximize_VB the_DT therapeutic_JJ characteristics_NNS of_IN this_DT potent_JJ molecule_NN while_IN minimizing_VBG the_DT potential_NN for_IN the_DT development_NN of_IN resistance_NN and_CC ensuring_VBG a_DT high_JJ level_NN of_IN treatment_NN compliance_NN ._SENT 